[go: up one dir, main page]

SK2942003A3 - Chromenone derivatives and their use for treating diseases in conjunction with 5-HTA1 receptors and/or dopamine D2 receptors - Google Patents

Chromenone derivatives and their use for treating diseases in conjunction with 5-HTA1 receptors and/or dopamine D2 receptors Download PDF

Info

Publication number
SK2942003A3
SK2942003A3 SK294-2003A SK2942003A SK2942003A3 SK 2942003 A3 SK2942003 A3 SK 2942003A3 SK 2942003 A SK2942003 A SK 2942003A SK 2942003 A3 SK2942003 A3 SK 2942003A3
Authority
SK
Slovakia
Prior art keywords
formula
treatment
chromenone derivative
acceptable salts
physiologically acceptable
Prior art date
Application number
SK294-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Rudolf Gottschlich
Karl-August Ackermann
Helmut Prucher
Christoph Seyfried
Gert Bartoszyk
Amsterdam Christoph Van
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SK2942003A3 publication Critical patent/SK2942003A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK294-2003A 2000-08-24 2001-07-24 Chromenone derivatives and their use for treating diseases in conjunction with 5-HTA1 receptors and/or dopamine D2 receptors SK2942003A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10041574A DE10041574A1 (de) 2000-08-24 2000-08-24 Chromenonderivate
PCT/EP2001/008528 WO2002016354A1 (fr) 2000-08-24 2001-07-24 Derives de chromenone et leur utilisation pour traiter des affections en rapport avec des recepteurs de 5-hta1 et/ ou des recepteurs d2 de dopamine

Publications (1)

Publication Number Publication Date
SK2942003A3 true SK2942003A3 (en) 2003-09-11

Family

ID=7653636

Family Applications (1)

Application Number Title Priority Date Filing Date
SK294-2003A SK2942003A3 (en) 2000-08-24 2001-07-24 Chromenone derivatives and their use for treating diseases in conjunction with 5-HTA1 receptors and/or dopamine D2 receptors

Country Status (16)

Country Link
US (1) US20040014768A1 (fr)
EP (1) EP1311503A1 (fr)
JP (1) JP2004506733A (fr)
KR (1) KR20030022390A (fr)
CN (1) CN1447807A (fr)
AU (1) AU2001289735A1 (fr)
BR (1) BR0113364A (fr)
CA (1) CA2420206A1 (fr)
CZ (1) CZ2003659A3 (fr)
DE (1) DE10041574A1 (fr)
MX (1) MXPA03001609A (fr)
NO (1) NO20030811D0 (fr)
PL (1) PL359222A1 (fr)
SK (1) SK2942003A3 (fr)
WO (1) WO2002016354A1 (fr)
ZA (1) ZA200302255B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2323451T7 (es) * 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
DE602005023285D1 (de) * 2004-03-26 2010-10-14 Lg Electronics Inc Speichermedium,verfahren, und gerät zum wiedergeben von untertiteldatenströmen
BRPI0509270A (pt) 2004-03-26 2007-09-04 Lg Electronics Inc meio de gravação, método e aparelho para reproduzir fluxo de subtìtulo de texto
KR20130132932A (ko) 2010-12-20 2013-12-05 아스트라제네카 아베 2-카르복스아미드-4-피페라지닐-벤조푸란 유도체
CN104059046B (zh) * 2013-03-18 2017-02-08 江苏恩华药业股份有限公司 黄酮类衍生物及其应用
CN116332918B (zh) * 2023-03-17 2025-07-25 遵义医科大学珠海校区 香豆素-喹啉衍生物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
DE4111861A1 (de) * 1991-04-11 1992-10-15 Schwabe Willmar Gmbh & Co Benzopyranone, verfahren zu ihrer herstellung und verwendung

Also Published As

Publication number Publication date
CA2420206A1 (fr) 2003-02-21
NO20030811L (no) 2003-02-21
DE10041574A1 (de) 2002-03-07
CN1447807A (zh) 2003-10-08
BR0113364A (pt) 2003-07-15
CZ2003659A3 (cs) 2003-06-18
JP2004506733A (ja) 2004-03-04
US20040014768A1 (en) 2004-01-22
AU2001289735A1 (en) 2002-03-04
ZA200302255B (en) 2004-08-16
NO20030811D0 (no) 2003-02-21
PL359222A1 (en) 2004-08-23
KR20030022390A (ko) 2003-03-15
WO2002016354A1 (fr) 2002-02-28
MXPA03001609A (es) 2003-06-04
EP1311503A1 (fr) 2003-05-21

Similar Documents

Publication Publication Date Title
TWI568728B (zh) 雜環化合物及彼之用途
EP4194459A1 (fr) Procédé de préparation d'un dérivé de pyridone polycyclique substitué et cristal de celui-ci
TWI722004B (zh) 1,3,5-三嗪衍生物及其使用方法
US20230406854A1 (en) Covalent kras-binding compounds for therapeutic purposes
CZ289449B6 (cs) 3-[4-(4-(4-Kyanfenyl)-1-piperazinyl)butyl]-5-kyanindol, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
CN101851237B (zh) 一种螺环化合物及其制备方法和应用
KR101710740B1 (ko) 2-［［［2-［(히드록시아세틸)아미노］-4-피리디닐］메틸］티오］-ｎ-［4-(트리플루오로메톡시)페닐］-3-피리딘카르복사미드의 벤젠술폰산염, 이의 결정, 이의 결정 다형 및 이들의 제조 방법
SK2942003A3 (en) Chromenone derivatives and their use for treating diseases in conjunction with 5-HTA1 receptors and/or dopamine D2 receptors
CN102108078B (zh) 1,4-取代酞嗪类化合物及其制备方法和用途
CN105153026B (zh) 含联芳基酰胺结构的索拉非尼衍生物及其制备方法和应用
SK3612003A3 (en) Arylpiperazine derivatives and their use as psychotropic agents
TW202426443A (zh) 雜環類衍生物抑制劑的鹽、晶型及其製備方法和應用
US7425574B2 (en) Benzofuran oxyethylamines as antidepressants and anxiolytics
SK17122002A3 (sk) Derivát heterocyklického aminoalkylpyridínu ako psychofarmaceutické činidlo, spôsob jeho prípravy, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje
CZ327494A3 (en) Esters of nicotinic acid and process for preparing thereof
JP7144863B2 (ja) イソキノリン化合物、その調製の方法、およびベータガラクトシダーゼの活性の変質に伴う状態におけるその治療的使用
JP2025511343A (ja) Ｎ－置換キノリノン化合物、その製造方法及びその使用
TWI867817B (zh) 一種二噁烷並喹啉類化合物的鹽、其晶型以及它們的製備方法及用途
MXPA05008437A (es) Derivados de benzofurano y el uso de los mismos como antidepresivos y ansioliticos.
CN108752360B (zh) 一种治疗小儿腹泻的化合物及其制备方法
WO2025094117A1 (fr) Composés indolyles substitués, leurs compositions et leurs utilisations thérapeutiques
CN103113365B (zh) 罗丹宁喹唑啉胺复合物及其制备方法和用途
CN107304180B (zh) 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
WO2023010354A1 (fr) Composé à petites molécules ayant une activité inhibitrice de l'egfr, son procédé de préparation et son utilisation
WO2022037601A1 (fr) Dérivé de pyrazolamide servant d'antagoniste du récepteur ep4 et son utilisation dans la préparation de médicaments pour le traitement du cancer et de l'inflammation